glutathione binding site gst S-transferase 786-993

For people with type 2 diabetes, the SURPASS trial series demonstrated exceptional glycemic control alongside weight loss, which is why the compound received its first approval for diabetes before the obesity indication followed

It is orally bioavailable

By selectively recruiting LXR coregulators, GF2 reduces hepatic lipid accumulation and suppresses inflammation of identify GF2 as a promising therapeutic candidate for metabolic liver diseases ( Ginsenoside Rh4 alleviates non-alcoholic fatty liver disease (NAFLD) by modulating the gutliver axis

Koundouros N, Poulogiannis G

S + 1 = 2.0 + 1 = 1) can be effectively used in anticancer therapy, involving photodynamic therapy (PDT) (Maharjan and Bhattarai 2022)